Surmodics (NASDAQ: SRDX)

2d ago, source: The Motley Fool

Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic immunoassay tests and microarrays.

Here's Why You Should Hold Surmodics (SRDX) Stock for Now

29d ago, source: Zacks.com on MSN

Surmodics, Inc. SRDX is well-poised for growth in the coming quarters, courtesy of its solid prospects in the thrombectomy ...

Should You Think About Buying Surmodics, Inc. (NASDAQ:SRDX) Now?

26d ago, source: Yahoo Finance

Surmodics, Inc. (NASDAQ:SRDX), is not the largest company out there, but it saw significant share price movement during recent months on the NASDAQGS, rising to highs of US$38.49 and falling to ...

New Strong Buy Stocks for April 9th

Opinion ago, source: Zacks.com on MSN

List today: Surmodics, Inc. SRDX: This medical device coating technology provider has seen the Zacks Consensus Estimate for ...

Surmodics to Participate in Upcoming Investor Conferences in March and April

1mon ago, source: Stockhouse

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that management will participate in the following ...

Are Surmodics, Inc.'s (NASDAQ:SRDX) Mixed Financials Driving The Negative Sentiment?

1mon ago, source: Yahoo Finance

Surmodics (NASDAQ:SRDX) has had a rough month with its share price down 8.9%. It is possible that the markets have ignored the company's differing financials and decided to lean-in to the negative ...

Surmodics, Inc.

1mon ago, source: U.S. News & World Report

Some funds make more sense to hold in a Roth IRA due to higher income generation, greater turnover or the potential for stronger long-term growth.

Analysts Offer Insights on Healthcare Companies: Genprex (GNPX) and SurModics (SRDX)

8d ago, source:

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Genprex (GNPX – Research Report) and ...

Investors in Surmodics (NASDAQ:SRDX) have unfortunately lost 54% over the last three years

5d ago, source:

If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly.